Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome

[1]  Jeroen J. Bax,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines , 2016, European journal of heart failure.

[2]  Héctor Bueno,et al.  Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica , 2016 .

[3]  W. Haverkamp,et al.  Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non‐small cell lung cancer: results of a prospective cardiovascular long‐term study , 2016, European journal of heart failure.

[4]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[5]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[6]  C. Grines,et al.  Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue , 2016, Circulation.

[7]  Morten Wang Fagerland,et al.  Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol , 2016, European heart journal.

[8]  K. Murphy.  The pathogenesis and treatment of cardiac atrophy in cancer cachexia. , 2016, American journal of physiology. Heart and circulatory physiology.

[9]  K. Swedberg,et al.  2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases. , 2015, Revista espanola de cardiologia.

[10]  Susanna Price,et al.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). , 2015, European heart journal.

[11]  P. Pellikka,et al.  Early and Late Outcomes of Surgical Treatment in Carcinoid Heart Disease. , 2015, Journal of the American College of Cardiology.

[12]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the diagnosis and management of pericardial diseases , 2015, European heart journal.

[13]  I. Abraham,et al.  Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis , 2015, Postgraduate Medical Journal.

[14]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[15]  M. Berry,et al.  Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. , 2015, Lung cancer.

[16]  J. Tamargo,et al.  Cancer Chemotherapy and Cardiac Arrhythmias: A Review , 2015, Drug Safety.

[17]  P. Charron,et al.  The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) , 2015 .

[18]  K. Swedberg,et al.  [2015 ESC Guidelines for the diagnosis and management of pericardial diseases]. , 2015, Kardiologia polska.

[19]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.

[20]  S. Anker,et al.  Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. , 2014, Journal of the American College of Cardiology.

[21]  James C Yao,et al.  Octreotide long‐acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population‐based analysis , 2014, Cancer.

[22]  Paaladinesh Thavendiranathan,et al.  Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. , 2014, Journal of the American College of Cardiology.

[23]  S. Darby,et al.  Cardiovascular disease after cancer therapy , 2014, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[24]  R. Touyz,et al.  Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. , 2014, The Canadian journal of cardiology.

[25]  C. Thomssen,et al.  Cardiotoxicity and oncological treatments. , 2014, Deutsches Arzteblatt international.

[26]  A. Drohomirecka,et al.  Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. , 2013, International journal of cardiology.

[27]  M. Bansal.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013 .

[28]  J. Dewyngaert,et al.  Ischemic heart disease after breast cancer radiotherapy. , 2013, The New England journal of medicine.

[29]  Matthew C. Altman,et al.  Omalizumab for chronic urticaria. , 2013, The New England journal of medicine.

[30]  J. Mariani,et al.  Cardiac complications of thoracic irradiation. , 2013, Journal of the American College of Cardiology.

[31]  J. Esteve,et al.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013, Journal of the American College of Cardiology.

[32]  G. Mantovani,et al.  Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate , 2013, SpringerPlus.

[33]  H. Sørensen,et al.  Endocarditis and risk of cancer: a Danish nationwide cohort study. , 2013, The American journal of medicine.

[34]  H. Eckstein.  S3-Leitlinie zur „Diagnostik, Therapie und Nachsorge der extracraniellen Carotisstenose“ , 2012, Gefässchirurgie.

[35]  Sudeep Gupta,et al.  Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature. , 2012, Journal of cancer research and therapeutics.

[36]  S. Barni,et al.  Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  D. Heigener,et al.  Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[38]  S. Bhatia.  Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[39]  D. Feldman,et al.  High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Kallmes,et al.  Outcomes of carotid artery stenting versus historical surgical controls for radiation-induced carotid stenosis. , 2011, Journal of vascular surgery.

[41]  R. Arceci,et al.  Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study , 2011 .

[42]  S. Zimeras,et al.  Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up , 2010, American journal of hematology.

[43]  S. Fosså,et al.  Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Ristic,et al.  Evaluation and management of pericardial effusion in patients with neoplastic disease. , 2010, Progress in cardiovascular diseases.

[45]  Michael S. Ewer,et al.  Cardiotoxicity of anticancer treatments: what the cardiologist needs to know , 2010, Nature Reviews Cardiology.

[46]  T. Choueiri,et al.  Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Y. Arima,et al.  Sorafenib-induced acute myocardial infarction due to coronary artery spasm. , 2009, Journal of cardiology.

[48]  M. Degertekin,et al.  Paclitaxel‐induced ST‐Segment Elevations , 2009, Clinical cardiology.

[49]  J. Soria,et al.  Review Management of Hypertension in Angiogenesis Inhibitor-treated Patients , 2022 .

[50]  N. Saijo,et al.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811) , 2009, British Journal of Cancer.

[51]  W. Gradishar,et al.  American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  P. Sengupta,et al.  Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. , 2009, The oncologist.

[53]  Shenhong Wu,et al.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.

[54]  W. Tsai,et al.  Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Y. Hosomi,et al.  [Treatment of malignant pericardial effusion]. , 2008, Gan to kagaku ryoho. Cancer & chemotherapy.

[56]  Gary H Lyman,et al.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Streiff,et al.  Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. , 2007, The oncologist.

[58]  L. Wojnowski,et al.  Genotyping the risk of anthracycline-induced cardiotoxicity , 2007, Cardiovascular Toxicology.

[59]  K. Aytemir,et al.  Early and Late Arrhythmogenic Effects of Doxorubicin , 2007, Southern medical journal.

[60]  A. Horwich,et al.  Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. , 2007, Journal of the National Cancer Institute.

[61]  P. Richardson,et al.  Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. , 2006, JAMA.

[62]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[63]  H. Chew,et al.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.

[64]  S Seeber,et al.  Risk factors for venous thromboembolic events in cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  R. Fisher,et al.  Thromboembolism in hospitalized neutropenic cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  A. Khorana,et al.  Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study , 2005, Cancer.

[67]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[68]  S. Lipshultz,et al.  Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies , 2005, British journal of haematology.

[69]  T. Barbui,et al.  Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study , 2005, British journal of haematology.

[70]  S. Lippman,et al.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  F. Rosendaal,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[72]  Stephen W. K. Cheng,et al.  Accelerated progression of carotid stenosis in patients with previous external neck irradiation. , 2004, Journal of vascular surgery.

[73]  N. Vogelzang,et al.  Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[74]  S. Soignet,et al.  Effect of arsenic trioxide on QT interval in patients with advanced malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[76]  D. Keefe,et al.  Trastuzumab‐associated cardiotoxicity , 2002, Cancer.

[77]  F. Buonanno,et al.  Acute Ischemic Stroke Patterns in Infective and Nonbacterial Thrombotic Endocarditis: A Diffusion-Weighted Magnetic Resonance Imaging Study , 2002, Stroke.

[78]  lexander,et al.  Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer , 2002 .

[79]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[80]  T. Ley,et al.  Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. , 2001, Blood.

[81]  D. Mouratidou,et al.  Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa). , 2000, The American journal of cardiology.

[82]  D J van Veldhuisen,et al.  Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  W M O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[84]  S. Mineishi,et al.  Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation , 2000, Bone Marrow Transplantation.

[85]  E. Monti,et al.  Role of iron in anthracycline cardiotoxicity: new tunes for an old song? , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[86]  J. R. Stewart,et al.  Radiation injury to the heart. , 1995, International journal of radiation oncology, biology, physics.

[87]  M. Christian,et al.  A reassessment of cardiac toxicity associated with Taxol. , 1993, Journal of the National Cancer Institute. Monographs.

[88]  J. Silber,et al.  Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. , 1992, The American journal of cardiology.

[89]  E. S. Hansen.  International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/2. Shared risk factors for cancer and atherosclerosis--a review of the epidemiological evidence. , 1990, Mutation research.

[90]  E. Cho,et al.  Cerebral infarction from non-bacterial thrombotic endocarditis. Clinical and pathological study including the effects of anticoagulation. , 1987, The American journal of medicine.

[91]  M. Fishbein,et al.  Nonbacterial thrombotic endocarditis: a review. , 1987, American heart journal.

[92]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[93]  T. Reagan,et al.  The thrombotic syndrome associated with carcinoma. A clinical and neuropathologic study. , 1974, Archives of neurology.